CC 11006
Alternative Names: CC-11006Latest Information Update: 02 Oct 2021
At a glance
- Originator Celgene Corporation
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators; Interleukin 1 beta inhibitors; Interleukin 10 stimulants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Inflammation; Myelodysplastic syndromes
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 31 Oct 2006 Preclinical trials in Amyotrophic lateral sclerosis in USA (PO)
- 31 Oct 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the Neurological disorders pharmacodynamics section